Drug Profile
Hepatitis B vaccine recombinant - Beijing Minhai Biotechnology
Alternative Names: Recombinant Hepatitis B vaccine - Beijing Minhai BiotechnologyLatest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Beijing Minhai Biotechnology
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for phase-I development in Hepatitis-B(Prevention) in China (Parenteral, Injection)
- 02 Sep 2015 Phase-I clinical trials in Hepatitis B (Prevention) in China (Parenteral) before September 2015